New shot aims to boost platelets in rare bleeding disorder

NCT ID NCT06880081

First seen Mar 10, 2026 · Last updated May 02, 2026 · Updated 5 times

Summary

This early study tests a new drug called PN20 in 12 adults with primary immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, raising bleeding risk. Participants receive one injection and are monitored for safety and platelet count changes. The goal is to see if PN20 is safe and might help control the disease.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PRIMARY IMMUNE THROMBOCYTOPENIA (ITP) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Affiliated Hospital of Guizhou Medical University

    RECRUITING

    Guiyang, Guizhou, 550004, China

    Contact

  • Hematology Hospital of Chinese Academy of Medical Sciences

    RECRUITING

    Tianjin, Tianjin Municipality, 301609, China

    Contact

  • Jining First People's Hospital

    RECRUITING

    Jining, Shandong, 272011, China

    Contact

  • The Second Affiliated Hospital of Kunming Medical University

    RECRUITING

    Kunming, Yunnan, 650000, China

    Contact

  • The Second Affiliated Hospital of Nanchang University

    RECRUITING

    Nanchang, Jiangxi, 330006, China

    Contact

Conditions

Explore the condition pages connected to this study.